Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.

BofA reinstated coverage of Moderna (MRNA) with an Underperform rating and $41 price target calling it “a tough time to be a ...

Moderna (MRNA) shares tumble after Bank of America analysts reinstated its Underperform rating for the stock. In a broader note about the pharmaceutical and biotech spaces, Bank of America's team it's ...

BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly (LLY), Gilead (GILD) and Merck ...

On Tuesday, Moderna Inc (MRNA) stock saw a decline, ending the day at $41.51 which represents a decrease of $-4.14 or -9.07% from the prior close of $45.65. The stock opened at $45.36 and touched a ...

BofA (BAC) analysts restarted their coverage on 11 large-capitalization pharmaceutical and biotech firms. The bad news was ...

CPI data matched expectations; Goods inflation rose to its highest level since May 2023. Albertson’s terminates merger with ...

S&P 500 E-Mini futures (ESZ24) are trending up +0.10% this morning as investors awaited the all-important U.S. inflation ...

Wall Street's main indexes closed lower on Tuesday as technology sector losses offset gains in communications services while ...

Wall Street's main indices closed lower on Tuesday as technology sector losses offset gains in communications services while ...

Shares of Pfizer, Moderna and other drugmakers fell at the ... Meanwhile, strategists at BofA Global Research said the risks to their forecast of 2.3% economic growth next year were “very ...